Have you looked into how Charles River Laboratories (CRL) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this medical research equipment and services provider, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.
The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.
While analyzing CRL's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter stood at $1 billion, declining 2.7% year over year. Now, let's delve into CRL's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
Unveiling Trends in CRL's International Revenues
Of the total revenue, $13.12 million came from Other International, including Brazil and Israel during the last fiscal quarter, accounting for 1.3%. This represented a surprise of +102.75% as analysts had expected the region to contribute $6.47 million to the total revenue. In comparison, the region contributed $9.4 million, or 0.9%, and $10.33 million, or 1%, to total revenue in the previous and year-ago quarters, respectively.
Canada accounted for 12.7% of the company's total revenue during the quarter, translating to $127.51 million. Revenues from this region represented a surprise of +8.19%, with Wall Street analysts collectively expecting $117.86 million. When compared to the preceding quarter and the same quarter in the previous year, Canada contributed $109.57 million (11%) and $135.59 million (13.1%) to the total revenue, respectively.
During the quarter, Europe contributed $263.07 million in revenue, making up 26.2% of the total revenue. When compared to the consensus estimate of $257.15 million, this meant a surprise of +2.3%. Looking back, Europe contributed $277.58 million, or 27.9%, in the previous quarter, and $281.86 million, or 27.3%, in the same quarter of the previous year.
Asia Pacific generated $60.52 million in revenues for the company in the last quarter, constituting 6% of the total. This represented a surprise of +18.13% compared to the $51.23 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia Pacific accounted for $55.48 million (5.6%), and in the year-ago quarter, it contributed $54.5 million (5.3%) to the total revenue.
Anticipated Revenues in Overseas Markets
Wall Street analysts expect Charles River to report a total revenue of $953.04 million in the current fiscal quarter, which suggests a decline of 5.2% from the prior-year quarter. Revenue shares from Other International, including Brazil and Israel, Canada, Europe and Asia Pacific are predicted to be 1.1%, 12.1%, 26.2%, and 4.4%, corresponding to amounts of $10.72 million, $114.84 million, $249.42 million, and $42.21 million, respectively.
For the full year, the company is projected to achieve a total revenue of $3.85 billion, which signifies a fall of 4.1% from the last year. The share of this revenue from various regions is expected to be: Other International, including Brazil and Israel at 1% ($40.1 million), Canada at 11.9% ($459.08 million), Europe at 27% ($1.04 billion), and Asia Pacific at 5.3% ($202.41 million).
Closing Remarks
Charles River's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.
In an era of growing international interdependencies and escalating geopolitical disputes, Wall Street analysts are vigilant in tracking these trends for businesses with a global reach, in order to refine their predictions of earnings. It should be noted, however, that a multitude of other elements, such as a company's domestic position, also play a significant role in shaping the earnings forecasts.
At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.
Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.
Charles River, bearing a Zacks Rank #2 (Buy), is expected to outperform the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Charles River Laboratories' Recent Stock Market Performance
Over the preceding four weeks, the stock's value has appreciated by 14.6%, against an upturn of 3.4% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts Charles River among its entities, has depreciated by 0.4%. Over the past three months, the company's shares have seen an increase of 77.3% versus the S&P 500's 6% increase. The sector overall has witnessed an increase of 10.8% over the same period.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Â

(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.